AbCellera Biologics (8QQ) AI Stock Analysis
AbCellera Biologics
(Frankfurt:8QQ)
No summary available
AbCellera Biologics (8QQ) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 3.60B
- Dividend Yield
- ―
- Average Volume (3M)
- 1,222
- Price to Earnings (P/E)
- -20.6
- Beta (1Y)
- 1.37
- Revenue Growth
- 90.86%
- EPS Growth
- 9.25%
- Country
- Germany
- Employees
- 562
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AbCellera Biologics Business Overview & Revenue Model
Company Description
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation o...
AbCellera Biologics Earnings Call Summary
The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that a top‑line readout for ABCL635 (postmenopausal VMS) is expected "very soon" after enrollment and initial dosing completed in June, with the Phase II top‑line reporting 4‑week data only (single dose, no re‑dosing) and they’re targeting a clinically meaningful frequency improvement of roughly 20% vs placebo and ≥2 fewer hot flashes/day; ABCL575 Phase I dosing is complete with a readout on track for Q4 (no plans to develop beyond Phase I), ABCL‑688 and ABCL386 are expected to enter Phase I/II in 2027, and one planned IND‑enabling move in H1 was missed but progress continues. Financial guidance/metrics: Q2 revenue ≈$4M (vs ≈$17M y/y), R&D ≈$46M (up ≈$7M y/y), SG&A ≈$14M (down from $22M), net loss ≈$55M (vs $35M) and loss per share $0.18; cash and marketable securities ≈$565–567M with $420M invested in short‑term securities, roughly $110M of available committed government funding (total available liquidity >$675M including unused government funding), operating cash used ≈$8M in H1 (including $56M upfront from Jazz), YTD capex ≈$6M, $7M in government grants received, and $15M invested in marketable securities this quarter. Strategic deal metrics: recent TCE collaborations bring $28M upfront from Vertex and $84M near‑term from Jazz (total >$110M upfront), $56M of Jazz upfront received to date with another $28M due, potential Jazz downstream payments >$2B and total program deal value >$4B, plus mid‑single to low‑double‑digit tiered royalties; management says liquidity supports at least the next 3 years of pipeline investment.
AbCellera Biologics Risk Analysis
AbCellera Biologics disclosed 99 risk factors in its most recent earnings report. AbCellera Biologics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksAbCellera Biologics Peers Comparison
Overall Rating
ABSI66Neutral
ZYME59Neutral
RXRX57Neutral
XNCR47.4Neutral
GENB42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ABSI | 66Neutral | $1.91B | -12.11 | -59.21% | ― | -62.28% | 15.36% |
| ZYME | 59Neutral | $2.03B | -14.35 | -72.07% | ― | -69.78% | -106.07% |
| RXRX | 57Neutral | $2.41B | -4.25 | -50.41% | ― | -15.08% | 41.98% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| XNCR | 47Neutral | $2.22B | -13.67 | -28.66% | ― | -28.56% | 10.25% |
| GENB | 42Neutral | $1.86B | -7.82 | -153.12% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:8QQ | Abcellera Biologics, Inc. | 11.30 | 6.80 | 150.89% | |
| XNCR | Xencor Inc. | 29.66 | 15.96 | 116.50% | |
| ZYME | Zymeworks | 28.99 | 10.83 | 59.64% | |
| RXRX | Recursion Pharmaceuticals, Inc | 3.83 | -1.17 | -23.40% | |
| ABSI | Absci Corp. | 9.69 | 5.75 | 145.94% | |
| GENB | Generate Biomedicines, Inc. | 13.21 | 0.56 | 4.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.